NEW YORK (AP) — NEW YORK (AP) — Intra-Cellular Therapies Inc. (ITCI) on Wednesday reported a loss of $26.3 million in its third quarter.
The New York-based company said it had a loss of 25 cents per share.
The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for a loss of 18 cents per share.
The biopharmaceutical company posted revenue of $175.4 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $171.7 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ITCI at https://www.zacks.com/ap/ITCI
Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
